Therapeutic Effect of mRNA SARS-CoV-2 Vaccine on Melanoma Skin Metastases.

antitumor activity apoptotic activity mRNA SARS-CoV-2 vaccine melanoma melanoma metastasis melanoma skin metastasis

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
28 Mar 2022
Historique:
received: 02 03 2022
revised: 25 03 2022
accepted: 25 03 2022
entrez: 23 4 2022
pubmed: 24 4 2022
medline: 24 4 2022
Statut: epublish

Résumé

A unique case of multiple metastatic melanoma skin nodules regression in a heavily pretreated, 72-year-old Caucasian female, after administering the second dose of the SARS-CoV-2 mRNA Pfizer-BioNTech vaccine, is presented. Two days after vaccination, all her melanoma skin nodules became painful and were significantly reduced in size. Physical examination and ultrasound imaging confirmed the patient's observation. The effect was sustained, and further reduction of the nodules occurred after the third vaccine dose. One of the reduced nodules was removed, histologically examined, and its histopathology was compared to that of another such nodule removed and examined earlier. Distinct differences were observed between the two histopathologies, with the most notable the unexpected finding of the absence of infiltrating lymphocytes in the reducer nodule's melanoma tissue. Based on this observation, the possible immunological mechanism(s) leading to the vaccine's effect are speculated. More possible is the vaccine's antitumor and apoptotic activity via stimulation of the Tol Like Receptors 3, 7, and 8, and (downstream) the nuclear factor kappa-light-chain-enhancer of the activated B cells pathway of the non-lymphocytic immune effector cells.

Identifiants

pubmed: 35455274
pii: vaccines10040525
doi: 10.3390/vaccines10040525
pmc: PMC9025412
pii:
doi:

Types de publication

Case Reports

Langues

eng

Références

Mol Cancer. 2021 Apr 15;20(1):69
pubmed: 33858437
N Engl J Med. 2021 Jun 10;384(23):2229-2240
pubmed: 34107182
Oncoimmunology. 2016 Oct 18;5(11):e1232237
pubmed: 27999747
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
Arch Razi Inst. 2021 Mar;76(1):1-6
pubmed: 33818952
Cancer Biol Ther. 2019;20(11):1366-1379
pubmed: 31366280
Oncoimmunology. 2016 Oct 24;5(12):e1249090
pubmed: 28123886
Mol Cancer. 2021 Feb 25;20(1):41
pubmed: 33632261
Cancer. 2020 Jan 1;126(1):86-97
pubmed: 31584722
Mol Cancer. 2021 Mar 15;20(1):52
pubmed: 33722265
Cancers (Basel). 2020 Feb 19;12(2):
pubmed: 32092958
Front Pharmacol. 2017 May 31;8:304
pubmed: 28620298

Auteurs

Dimitrios Bafaloukos (D)

First Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece.

Kalliopi Petraki (K)

Department of Pathology, Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece.

Aikaterini Bousmpoukea (A)

First Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece.

Eleni Chatzichristou (E)

First Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece.

Ioannis Pieris (I)

Department of Radiology, Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece.

Christos Koutserimpas (C)

Department of Orthopaedics and Traumatology, "251" Hellenic Air Force General Hospital, 18547 Athens, Greece.

George Samonis (G)

First Oncology Department, Metropolitan Hospital, Neon Faliron, 18547 Athens, Greece.

Classifications MeSH